Neurologic clinical trial - PhaseBio Ticagrelor Reversal Study

CONDITIONS: Brain Bleed, Intracranial hemorrhage, hemorrhage, urgent surgery, invasive procedure - TRIAL: A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure

Drug

Bentracimab (PB2452) Infusion

Phase

Phase 3

Condition

Brain bleed Intracranial hemorrhage hemorrhage urgent surgery invasive procedure

Keywords

PhaseBio Pharmaceuticals Inc. | PB2452-PT-CL-0004